These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28036343)

  • 1. Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection.
    Maas BM; Francis O; Mollan KR; Lee C; Cottrell ML; Prince HM; Sykes C; Trezza C; Torrice C; White N; Malone S; Hudgens MG; Sharpless NE; Dumond JB
    PLoS One; 2016; 11(12):e0168709. PubMed ID: 28036343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.
    Dumond JB; Francis O; Cottrell M; Trezza C; Prince HM; Mollan K; Sykes C; Torrice C; White N; Malone S; Wang R; Van Dam C; Patterson KB; Hudgens MG; Sharpless NE; Forrest A
    Antivir Ther; 2016; 21(5):441-5. PubMed ID: 26731175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
    Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
    PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine.
    Dumond JB; Bay CP; Nelson JAE; Davalos A; Edmonds A; De Paris K; Sykes C; Anastos K; Sharma R; Kassaye S; Tamraz B; French AL; Gange S; Ofotokun I; Fischl MA; Vance DE; Adimora AA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p16
    Dumond JB; Collins JW; Cottrell ML; Trezza CR; Prince H; Sykes C; Torrice C; White N; Malone S; Wang R; Patterson KB; Sharpless NE; Forrest A
    CPT Pharmacometrics Syst Pharmacol; 2017 Feb; 6(2):120-127. PubMed ID: 28019088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
    Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
    HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
    Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
    HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
    Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
    Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
    Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
    McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Melbourne K; Ha B; Brown TT; Bloom A; Fedarko N; Sax PE
    AIDS; 2012 Jul; 26(11):1371-85. PubMed ID: 22546988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.
    Figueroa DB; Madeen EP; Tillotson J; Richardson P; Cottle L; McCauley M; Landovitz RJ; Andrade A; Hendrix CW; Mayer KH; Wilkin T; Gulick RM; Bumpus NN
    AIDS Res Hum Retroviruses; 2018 May; 34(5):421-429. PubMed ID: 29455571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
    Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
    N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
    Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
    J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
    Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
    Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
    Robertson K; Maruff P; Ross LL; Wohl D; Small CB; Edelstein H; Shaefer MS
    J Neurovirol; 2019 Feb; 25(1):22-31. PubMed ID: 30298202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.